Calithera Biosciences, Inc. has terminated development of its lead asset, telaglenastat, based on interim Phase II study data in lung cancer, forcing the company to re-shift its focus to two recently acquired oncology candidates.
Calithera Drops Development Of Lead Candidate Telaglenastat
Interim Phase II Lung Cancer Data Underwhelming
Calithera’s most advanced oncological asset, telaglenastat, has failed in yet another indication, prompting the company to fall back on candidates in-licensed from Takeda just last month.
